Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | CASP1 | P29466 | 1/20 | 0.51 |
| ▸ | CES2 | O00748 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.47 |
| ▸ | CFTR | P13569 | 1/20 | 0.46 |
| ▸ | PDE2A | O00408 | 2/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.45 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.44 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 2/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29753880 | 1.00 | ALDH1A1 (0.51) | ALDH1A1KDM4EHPGDHSD17B10CASP1 | |
| SCHEMBL629096 | 0.85 | CASP1 (0.55) | ALDH1A1KDM4EHPGDHSD17B10CASP1 | |
| Hydrochloric Acid SCHEMBL4373946 | 0.84 | CASP1 (0.54) | ALDH1A1KDM4EHPGDHSD17B10CASP1 | |
| SCHEMBL1455625 | 0.83 | CES2 (0.52) | ALDH1A1KDM4EHPGDHSD17B10CES2 | |
| SCHEMBL1818435 | 0.83 | KDM4E (0.62) | ALDH1A1KDM4EHPGDHSD17B10CASP1 | |
| SCHEMBL9202951 | 0.82 | MKNK1 (0.56) | KDM4ECASP1PDK2MKNK1MKNK2 | |
| SCHEMBL9859789 | 0.82 | NPSR1 (0.46) | ALDH1A1KDM4EHPGDHSD17B10CES2 | |
| SCHEMBL8617573 | 0.81 | KDM4E (0.61) | ALDH1A1KDM4EHPGDHSD17B10CASP1 | |
| SCHEMBL6495907 | 0.81 | PDE2A (0.50) | ALDH1A1KDM4EHPGDHSD17B10CES2 | |
| SCHEMBL9636953 | 0.81 | CES2 (0.50) | ALDH1A1KDM4EHPGDHSD17B10CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3448850-B1 | PIPERIDINYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2020-11-04 | — | — | EP | claimed |
| US-10428024-B2 | Piperidinyl derivatives | MERCK PATENT GMBH (DE) | 2019-10-01 | — | — | US | claimed |
| US-20190135753-A1 | PIPERIDINYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2019-05-09 | — | — | US | claimed |
| WO-2017186653-A1 | PIPERIDINYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2017-11-02 | — | — | WO | claimed |
| EP-2804865-B1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-12-23 | — | — | EP | claimed |
| EP-2681215-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-04-22 | — | — | EP | claimed |
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | claimed |
| WO-2007130712-A1 | SUBSTITUTED DIPIPERIDINE AS CCR2 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | JANSSEN PHARMACEUTICA, NV (BE) | 2007-11-15 | — | — | WO | claimed |
| US-20070197590-A1 | SUBSTITUTED DIPIPERIDINE CCR2 ANTAGONISTS | JANSSEN PHARMACEUTCA N.V. (BE) | 2007-08-23 | — | — | US | claimed |
| CN-118146127-A | Preparation method of 2-methylthio-4-trifluoromethyl benzonitrile | 北京颖泰嘉和生物科技股份有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-109071490-B | Piperidinyl derivatives | 默克专利股份公司 | 2021-04-06 | — | — | CN | disclosed |
| EP-3448850-B1 | PIPERIDINYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2020-11-04 | — | — | EP | disclosed |
| US-10428024-B2 | Piperidinyl derivatives | MERCK PATENT GMBH (DE) | 2019-10-01 | — | — | US | disclosed |
| US-20190135753-A1 | PIPERIDINYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2019-05-09 | — | — | US | disclosed |
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | disclosed |
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | ICAGEN, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| WO-2007130712-A1 | SUBSTITUTED DIPIPERIDINE AS CCR2 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | JANSSEN PHARMACEUTICA, NV (BE) | 2007-11-15 | — | — | WO | disclosed |
| US-20070197590-A1 | SUBSTITUTED DIPIPERIDINE CCR2 ANTAGONISTS | JANSSEN PHARMACEUTCA N.V. (BE) | 2007-08-23 | — | — | US | disclosed |
| US-7223782-B2 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197590-A1 | SUBSTITUTED DIPIPERIDINE CCR2 ANTAGONISTS | CCR2, CCR1, CCR5 | ALDH1A1 905/4885KDM4E 3992/4885HPGD 610/4885 |
| US-10428024-B2 | Piperidinyl derivatives | PDK1, PDK2, PDK3 | ALDH1A1 82/4885KDM4E 1034/4885HPGD 124/4885 |
| US-20190135753-A1 | PIPERIDINYL DERIVATIVES | PDK1, PDK2, PDK3 | ALDH1A1 82/4885KDM4E 1034/4885HPGD 124/4885 |
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | SCN3A, TRPV3, HCN3 | ALDH1A1 3589/4885KDM4E 2869/4885HPGD 1358/4885 |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | SCN3A, TRPV3, HCN3 | ALDH1A1 3589/4885KDM4E 2869/4885HPGD 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.